Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
| Last: | $13.22 |
|---|---|
| Change Percent: | 1.46% |
| Open: | $13.5 |
| Close: | $13.03 |
| High: | $13.73 |
| Low: | $13.14 |
| Volume: | 172,371 |
| Last Trade Date Time: | 02/27/2026 12:45:28 pm |
| Market Cap: | $427,420,977 |
|---|---|
| Float: | 29,130,961 |
| Insiders Ownership: | 0.22% |
| Institutions: | 43 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.graphitebio.com |
| Country: | US |
| City: | Solana Beach |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about LENZ Therapeutics Inc. (NASDAQ: LENZ).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
